Ligand Pharmaceuticals Inc. (LGND) Wednesday said it earned $6 million through the out-licensing of an antibody projects through its partner HanAll Biopharma. The antibody project has utilised Ligand's OmniAb antibody discovery platform.
from RTT - Earnings http://ift.tt/2EQZ9v1
via IFTTT
No comments:
Post a Comment